Rapid method of determining clearance of prion protein
AssigneeBayer HealthCare LLC
InventorsSteve R. Petteway, Douglas C. Lee, Robert W. Kozak
Life of this patent
Estimating the term…
Abstract
The invention provides a rapid, sensitive immunoassay capable of detecting and quantitating pathogenic protein to a level of 3 to 5 logs. The preferred immunoassay utilized is a chemiluminescent endpoint for a Western blot immunoassay. The invention has been successfully applied to track the clearance of pathogenic protein during production of proteins derived from plasma. It is particularly applicable and has been confirmed by bioassay to relate TSE infectivity to quantitative results on prion protein.
Claims24
An immunoassay method useful for quantitating pathogenic protein in a biological sample, comprising the steps of:
- a) preparing a relevant biological sample for an immunoassay;
- b) performing the immunoassay on the sample for pathogen protein;
- and
- c) quantitating the pathogen protein results.
An immunoassay method useful for determining the presence of TSE protein in a biological sample, comprising the steps of:
- a) preparing a relevant biological sample for a Western blot immunoassay;
- b) performing the Western blot immunoassay on such sample for TSE protein;
- and
- c) quantitating the TSE protein present.
Dependencies are inferred from the claim text.